<<返回上一页

Drug breakthrough starves prostate cancers

发布时间:2019-03-01 08:09:00来源:未知点击:

By Andy Coghlan and Angela Self Update: A phase III trial of abiraterone has successfully been shown to increase average survival rate for men with advanced prostate cancer. The trial, funded by Janssen Pharmaceutical Companies, included 1195 patients from 13 countries. The average overall survival among the group who received abiraterone plus the steroid prednisone was 14.8 months, compared with 10.9 months for those who received the steroid and a placebo. People on abiraterone were more likely to experience a significant drop in their prostate-specific antigen (PSA) levels, the standard measure of prostate cancer activity,